Skip to main content

Table 3 Prevalence of abnormal lipid profiles among patients treated with NRTIs and NNRTIs based antiretroviral regimens

From: Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon

NRTIs based regimens
Lipid profile AZT based (n = 82) TDF based (n = 75) p-value
Total cholesterol, mean ± SD 205.2 (66.3) 212.3 (77.8) 0.540
≥ 200 mg/dL 41 (50.0 %) 39 (52.0 %) 0.802
LDL-cholesterol, mean ± SD 115.9 (63.2) 119.5 (73.6) 0.744
≥ 130 mg/dL 27 (32.9 %) 31 (41.3 %) 0.276
HDL-cholesterol, mean ± SD 70.1 (29.9) 63.7 (25.6) 0.153
< 40 mg/dL 13 (15.9 %) 9 (12.0 %) 0.482
Triglycerides, mean ± SD 102.4 (46.9) 133.4 (67.1) 0.009
≥ 150 mg/dL 12 (14.6 %) 20 (26.7 %) 0.060
TC/HDL-cholesterol ratio, mean ± SD 3.6 (2.7) 3.9 (2.4) 0.405
≥ 5 12 (14.6 %) 12 (16.0 %) 0.808
NNRTIs based regimens
  NVP based (n = 101) EFV based (n = 43)  
Total cholesterol, mean ± SD 204.1 (65.5) 218.7 (90.6) 0.282
≥ 200 mg/dL 49 (48.5 %) 23 (53.5 %) 0.583
LDL-cholesterol, mean ± SD 114.6 (61.2) 126.5 (87.7) 0.353
≥ 130 mg/dL 36 (35.6 %) 17 (39.5 %) 0.657
HDL-cholesterol, mean ± SD 68.3 (29.5) 63.8 (22.5) 0.370
< 40 mg/dL 17 (16.8 %) 3 (7.0 %) 0.119
Triglycerides, mean ± SD 105.4 (29.5) 136.0 (75.4) 0.004
≥ 150 mg/dL 15 (14.9 %) 12 (27.9 %) 0.068
TC/HDL-cholesterol ratio, mean ± SD 3.6 (2.7) 3.9 (2.3) 0.635
≥ 5 16 (15.8 %) 7 (16.3 %) 0.940
  1. HAART- Highly Active Antiretroviral Therapy, TC-Total Cholesterol, HDL-High-Density Lipoprotein, LDL-Low- Density Lipoprotein, AZT-Zidovudine, TDF-Tenofovir, NVP-Nevirapine, EFV-Efavirenz, SD-Standard Deviation